Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 16,562 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 131,372 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 144,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 115,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001181556-26-000007 · form4-06052026_080631.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 605 | $36.80 | $22,264.00 |
DisclosureSEC source: 0001181556-26-000005 · form4-03172026_090352.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,237 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2025. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $22.34 | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · derivative · entry 7 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-02-01 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 115,500 | Not disclosed Strike: $14.22 | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · derivative · entry 6 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,500 shares Expires 2032-01-20 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 144,000 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · derivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,000 shares Expires 2033-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,489 | Not disclosed Strike: $39.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,489 shares Expires 2034-06-12 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,034 | Not disclosed Strike: $33.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 131,372 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:56 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 16,562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082154 · ownership.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:33 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,758 | $72.45 | $127,367.10 |
DisclosureSEC source: 0001599901-26-000022 · wk-form4_1769207624.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,562 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-26-000003 · form4-01052026_090116.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,211 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-26-000003 · form4-01052026_090116.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 23:36 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000228 · wk-form4_1766446557.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,320 F1 · shares: Represents a gift of shares to a Donor Advised Fund. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:47 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-25-000006 · form4-10012025_081019.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,211 Underlying: Common Stock · 1,211 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:47 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-25-000006 · form4-10012025_081019.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $22.34 | $0.00 |
DisclosureSEC source: 0001599901-25-000152 · wk-form4_1754689271.xml · derivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 107,500 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date of this Report. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 107,500 | $47.62 | $5,118,881.25 |
DisclosureSEC source: 0001599901-25-000152 · wk-form4_1754689271.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,650 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 107,500 | $22.34 | $2,401,550.00 |
DisclosureSEC source: 0001599901-25-000152 · wk-form4_1754689271.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019002 · form4-07022025_080722.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,422 Underlying: Common Stock · 1,210 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019002 · form4-07022025_080722.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:35 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 10,034 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001599901-25-000123 · wk-form4_1749767717.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · derivative.exercise_date: This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:35 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 6,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000123 · wk-form4_1749767717.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,650 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 00:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,747 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001415889-25-015701 · form4-06052025_120645.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,747 Underlying: Common Stock · 29,747 shares Expires 2035-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:03 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009616 · form4-04022025_080412.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,632 Underlying: Common Stock · 1,210 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:03 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009616 · form4-04022025_080412.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 22:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 4,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008712 · form4-03202025_100309.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,842 Underlying: Common Stock · 4,842 shares Expires 2025-12-31 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:17 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,872 | $28.60 | $53,536.77 |
DisclosureSEC source: 0001599901-25-000043 · wk-form4_1737681440.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,958 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.94. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 23:06 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,323 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000193 · wk-form4_1732143997.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,323 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All shares subject to the option have been exercised as of the date hereof. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 23:06 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 3,323 | $42.12 | $139,972.74 |
DisclosureSEC source: 0001599901-24-000193 · wk-form4_1732143997.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $43.35. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 23:06 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 3,323 | $1.24 | $4,120.52 |
DisclosureSEC source: 0001599901-24-000193 · wk-form4_1732143997.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000172 · wk-form4_1729714787.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $46.63 | $233,167.50 |
DisclosureSEC source: 0001599901-24-000172 · wk-form4_1729714787.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $48.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000172 · wk-form4_1729714787.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 21:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000154 · wk-form4_1726867140.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 21:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $45.73 | $228,658.00 |
DisclosureSEC source: 0001599901-24-000154 · wk-form4_1726867140.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.28 to $46.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 21:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000154 · wk-form4_1726867140.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000148 · wk-form4_1726007195.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By charitable remainder trust Disclosed balance after: 22,500 Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GiftCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-24-000148 · wk-form4_1726007195.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 131,372 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000146 · wk-form4_1724272228.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $45.19 | $225,946.50 |
DisclosureSEC source: 0001599901-24-000146 · wk-form4_1724272228.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $45.65. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000146 · wk-form4_1724272228.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000117 · wk-form4_1721766147.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $45.01 | $225,069.00 |
DisclosureSEC source: 0001599901-24-000117 · wk-form4_1721766147.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.20 to $45.38. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000117 · wk-form4_1721766147.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000113 · wk-form4_1719001171.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $37.59 | $187,950.50 |
DisclosureSEC source: 0001599901-24-000113 · wk-form4_1719001171.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.05 to $38.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:19 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000113 · wk-form4_1719001171.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 23:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 13,489 | $0.00 Strike: $39.96 | $0.00 |
DisclosureSEC source: 0001599901-24-000097 · wk-form4_1718406220.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,489 Underlying: Common Stock · 13,489 shares Expires 2034-06-12 F4 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 23:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 60,000 | $40.08 | $2,404,782.00 |
DisclosureSEC source: 0001599901-24-000097 · wk-form4_1718406220.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By family trust Disclosed balance after: 153,872 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on May 26, 2023 by the Reporting Person. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 23:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 40,000 | $35.07 | $1,402,628.00 |
DisclosureSEC source: 0001599901-24-000097 · wk-form4_1718406220.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By family trust Disclosed balance after: 213,872 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on May 26, 2023 by the Reporting Person. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.89. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.